Mr. Erqi Wang, Chairman of the Board of Directors and Chief Executive Officer of the Company, commented, "During the first half of fiscal year 2026, our revenue was affected by lower sales of other products and temporary foreign-exchange pressure on orders from our largest Japanese customer. Nevertheless, revenue from our core wheelchair products remained relatively stable, wheelchair component sales increased, and our gross margin improved to 26.9% as we continued to enhance inventory management and operating efficiency. We also increased investment in research and development to support product innovation and long-term growth. With $9.1 million in cash and $21.0 million in short-term investments as of March 31, 2026, we believe we maintain a solid financial position. Looking ahead, we will remain focused on strengthening our core product portfolio, expanding our customer base in China and overseas, advancing our production capacity, and exercising disciplined cost and working-capital management to navigate near-term market challenges and pursue sustainable growth."

First Half of Fiscal Year 2026 Financial Summary

• Total revenue was $8.9 million for the six months ended March 31, 2026, decreased by 9.7% from $9.9 million for the same period of last year.
  
  
• Gross profit remained relatively stable at $2.4 million for the six months ended March 31, 2026 and 2025.
  
  
• Gross margin was 26.9% for the six months ended March 31, 2026, compared to 24.3% for the same period of last year.
  
  
• Net loss was $0.2 million for the six months ended March 31, 2026, compared to net income of $0.01 million for the same period of last year.
  
  
• Basic and diluted loss per share were $0.01 for the six months ended March 31, 2026 and 2025.

First Half of Fiscal Year 2026 Financial Results

Revenue

Total revenue was $8.9 million for the six months ended March 31, 2026, decreased by 9.7% from $9.9 million for the same period of last year.

Revenue from wheelchair products remained relatively stable with a slight decrease of 1.4%, from $7.3 million for the six months ended March 31, 2025 to $7.1 million for the six months ended March 31, 2026. The decrease was mainly due to decreased sales of wheelchair products to our largest customer Nissin in Japan. Nissin purchases wheelchair products from us in RMB and sells them in Japanese Yen in Japan. However, due to the weakening of the Japanese Yen, profitability of Nissin was negatively impacted as their cost of wheelchair products increased. As a result, sales orders we received from Nissin decreased, and total sales to Nissin and its subsidiaries decreased by approximately $84,000 during the six months ended March 31, 2026. The management expects the impact of foreign currency fluctuation on our revenue from Nissin is temporary.

Revenue from wheelchair components increased by 9.9%, to $1.1 million for the six months ended March 31, 2026 from $1.0 million for the same period of last year. The increase was mainly due to more sales orders of wheelchair components we received during the six months ended March 31, 2026. Wheelchair components are ordered by our customers for their repair and maintenance purposes, and such orders fluctuate based on their estimated further demands.

Revenue from other products decreased by 59.1%, to $0.7 million for the six months ended March 31, 2026 from $1.6 million for the same period of last year. The decrease was mainly due to the decreased revenue of approximately $0.8 million from electric scooters, as the Company failed to obtain relevant qualifications and sales of electric scooters was ceased for the six months ended March 31, 2026.

Cost of Revenue and Related Tax

Cost of revenue and related tax decreased by 12.8%, to $6.5 million for the six months ended March 31, 2026, from $7.5 million for the same period of last year.

Gross Profit and Gross Margin

Gross profit remained relatively stable at $2.4 million for the six months ended March 31, 2026 and 2025.

Gross margin increased to 26.9% for the six months ended March 31, 2026, from 24.3% for the same period of last year. The increase was primarily attributable to higher variable costs for our standard and economy wheelchair products in the prior-year comparable period, when the Company utilized certain high-unit-price components without corresponding selling price increases to improve inventory turnover efficiency.

Operating Expenses

Operating expenses were $3.0 million for the six months ended March 31, 2026, compared to $2.9 million for the same period of last year.

• Our selling expenses decreased by 4.7%, to $0.71 million for the six months ended March 31, 2026, from $0.75 million for the same period of last year. The decrease was primarily attributable to lower exhibition expenses resulted from fewer trade show participations.
  
  
• Our general and administrative expenses remained relatively stable at $1.4 million for the six months ended March 31, 2026 and 2025.
  
  
• Our research and development expenses increased by 33.4%, to $0.9 million for the six months ended March 31, 2026, from $0.7 million for the same period of last year. The increase is primarily attributable to the increased research and development activities towards products development, and we invested in more manpower and materials during the six months ended March 31, 2026.

Other Income, Net

Our net other income increased by 344.5%, to $0.5 million for the six months ended March 31, 2026, from $0.1 million for the same period of last year. The increase in net other income was mainly due to higher government grants, consisting primarily of fixed asset investment subsidies for the factory construction project of our subsidiary Anhui Zhongjin.

Net Income (Loss)

Net loss was $0.2 million for the six months ended March 31, 2026, compared to net income of $0.01 million for the same period of last year.

Basic and Diluted Loss per Share

Basic and diluted loss per share were $0.01 for the six months ended March 31, 2026 and 2025.

Financial Condition

As of March 31, 2026, the Company had $9.1 million in cash as compared to $7.5 million as of September 30, 2025, and $21.0 million in short-term investments as compared to $22.2 million as of September 30, 2025. As of March 31, 2026, the Company also had approximately $5.5 million of account receivable balance due from third parties. Approximately 36.3% of the March 31, 2026 balance has been subsequently collected, and the majority of the remaining balance is expected to be collected by March 31, 2027. The collection of such receivables made cash available for use in the Company's operations as working capital, if necessary.

Net cash used in operating activities was $0.9 million for the six months ended March 31, 2026, mainly derived from a net loss of $0.2 million for the period, and net changes in our operating assets and liabilities, which mainly included a decrease in prepaid expenses and other current assets of $1.2 million.

Net cash provided by investing activities amounted to $0.2 million for the six months ended March 31, 2026, and primarily included the redemption of short-term investments of $4.6 million, which were partially offset by the payments for short-term investments of $2.6 million, and purchase of property, plant and equipment and payment for construction in progress of $1.8 million.

Net cash provided by financing activities amounted to $2.1 million for the six months ended March 31, 2026, which primarily included proceeds from short-term bank loans of $13.5 million and proceeds from long-term bank loan of $2.8 million, which was partially offset by repayments of short-term bank loans of $14.9 million. 

About JIN MEDICAL INTERNATIONAL LTD.

Founded in 2006 and headquartered at Changzhou, Jiangsu Province of China, Jin Medical designs, develops, manufactures and markets wheelchairs and living aids products for people with disabilities, elderly individuals, and for rehabilitation application. Currently, Jin Medical already operates two manufacturing plants of approximately 230,000 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. Jin Medical is currently establishing a new facility with 430,000 square feet in Chuzhou, Anhui Province, China. Jin Medical works with more than 40 distributors in China and more than 20 international distributors. The majority of Jin Medical's wheelchair products, with more than 30 models, are sold to distributors in Japan and China. Jin Medical continuously delivers innovative wheelchair products that are both lightweight and ergonomic. For more information, please visit: http://www.jinmed.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may", "will", "should", "intend", "plan", "strive", "believe", "expect", "anticipate", "project", "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company's ability to achieve its goals and strategies, the Company's future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, import and export restrictions, fluctuations in general economic and business conditions, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission ("SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

ir@jinmed.com 

The Company regained compliance after its Class A ordinary shares maintained a closing bid price of at least $1.00 per share for more than ten (10) consecutive business days.

The Company will continue to focus on its core business operations and ongoing strategic initiatives.

About Jin Medical International Ltd.

Founded in 2006 and headquartered at Changzhou, Jiangsu Province of China, Jin Medical designs, develops, manufactures and markets wheelchairs and living aids products for people with disabilities, elderlies, and for rehabilitation application. Currently, Jin Medical already operates two manufacturing plants of approximately 230,000 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. Jin Medical is currently establishing a new facility with 430,000 square feet in Chuzhou, Anhui Province, China. Jin Medical works with more than 40 distributors in China and more than 20 international distributors. The majority of Jin Medical's wheelchair products, with more than 30 models, are sold to distributors in Japan and China. Jin Medical continuously delivers innovative wheelchair products that are both lightweight and ergonomic. For more information, please visit: http://www.jinmed.com.

Forward-Looking Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may", "will", "should", "intend", "plan", "strive", "believe", "expect", "anticipate", "project", "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company's ability to achieve its goals and strategies, the Company's future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, import and export restrictions, fluctuations in general economic and business conditions, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission ("SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
ir@jinmed.com

The following questions were prepared by the Company and addressed by the Company's CEO, Dr. Erqi Wang during the conversation. Certain statements made during the discussion were forward-looking, and the Company provided a cautionary note regarding forward-looking statements prior to the start of the conversation.

1. Reverse Split

Question： At Jin Medical's recent extraordinary general meeting, shareholders were asked to approve a proposal authorizing the Company's board of directors to implement future reverse stock splits at specified ratios. Many investors view reverse splits as a compliance-driven move. What's your views on that?

Dr. Wang： I have observed reverse splits being often associated with compliance considerations, and we don't shy away from that reality.

In addition to potentially enabling us to regain compliance with Nasdaq's continuing listing standards, we view the reverse split as a strategic reset point. We hope that It will allow us to realign our capital structure with the Company's long-term fundamentals and improve market perception about our competitiveness. We hope it can be something more than just short-term price mechanics.

2. Strategic Plan to Long-Term Value Creation

Question: How is management thinking about the Company's priorities going forward, particularly in terms of execution, resource allocation and short-term and long-term operational focus? 

Dr. Wang:  Going forward, there are a few things in our priorities.

First, clear and consistent market communication. We intend to communicate our progress more frequently based on strategic and development goals and operational milestones, rather than short-term narratives.

Second, disciplined capital allocation. Our priority is to invest in manufacturing capability, product certification, and market expansion where we believe the return potential is strong, while maintaining prudent balance sheet management.

Third, we take a long-term oriented perspective and we plan to actively communicate that perspective to our shareholders — recognizing the industry cycle, the scale and duration of our manufacturing investments, and the time required to scale regulated medical products.

3. 2026–2027 Outlook

Question: Looking ahead to 2026 and 2027, can you share managements' current primary objectives?

Dr. Wang:   Our 2026-2027 objectives are driven by three goals:

• Broader commercialization following product certifications
• Manufacturing scale-up and cost normalization
• Expansion into regional and international markets

Underlying our assumptions is a disciplined approach to growth — prioritizing returns that we believe are repeatable and strengthen our operational stability over pursuing rapid growth that may be inconsistent or unsustainable.

4. Operating Leverage

Question: How should investors think about operating leverage? Where do you see the greatest opportunities to improve efficiency?

Dr. Wang: The most significant opportunities lie in manufacturing efficiency, supply chain integration, and product mix optimization. As fixed costs are absorbed across higher volumes and automation improves consistency, we believe margins can expand in a disciplined and sustainable manner.

5. Chuzhou New Factory – Strategic Importance

Questions: The Chuzhou new factory is a major investment for Jin Medical. Can you walk us through its strategic role — in terms of capacity expansion, cost structure, automation, and long-term competitiveness?

Dr. Wang: The Chuzhou facility is a cornerstone of our long-term manufacturing strategy. It is expected to launch full capacity production by the end of April 2026.

It is designed to support scalable capacity, improved automation, and tighter quality control. Over time, we believe it will lower unit costs, enhance production flexibility, and strengthen our ability to serve both domestic and international markets competitively.

6. Chuzhou Factory Timeline

Question: What is the expected timeline for ramp-up at the Chuzhou facility?

Dr. Wang: The ramp-up will be gradual and disciplined. Initial production will focus on selected product lines, followed by broader capacity utilization.

7. Industry Outlook

Question: From your perspective, how do you see the industry evolving over the next three to five years?

Dr. Wang: Over the next three to five years, we see strong structural demand driven by aging populations, rehabilitation needs, and rising healthcare quality expectations.

At the same time, the industry is moving toward higher standards in compliance, manufacturing, and technology integration — areas where scale, execution, and discipline matter.

8. US–China Relations & Risk Management

Question：US–China relations remain an important variable for global manufacturing companies. How does management assess the potential impact on Jin Medical, and what steps are being taken to manage geopolitical and supply chain risks?

Dr. Wang： We view geopolitical risk as a factor to be managed.

Our approach focuses on supply chain diversification, regional manufacturing flexibility, and regulatory compliance across markets. We believe these steps help ensure resilience regardless of external policy changes.

About Jin Medical International Ltd.

Founded in 2006 and headquartered at Changzhou, Jiangsu Province of China, Jin Medical designs, develops, manufactures and markets wheelchairs and living aids products for people with disabilities, elderlies, and for rehabilitation application. Currently, Jin Medical already operates two manufacturing plants of approximately 230,000 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. Jin Medical is currently establishing a new facility with 430,000 square feet in Chuzhou, Anhui Province, China. Jin Medical works with more than 40 distributors in China and more than 20 international distributors. The majority of Jin Medical's wheelchair products, with more than 30 models, are sold to distributors in Japan and China. Jin Medical continuously delivers innovative wheelchair products that are both lightweight and ergonomic. For more information, please visit: http://www.jinmed.com.

Forward-Looking Statement

This press release contains certain forward-looking statements made during the CEO Fireside Chat as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may", "will", "should", "intend", "plan", "strive",  "believe", "expect", "anticipate", "project", "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company's ability to achieve its goals and strategies, the Company's future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, import and export restrictions, fluctuations in general economic and business conditions, industry trend and outlook, geopolitical relations and challenges and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission ("SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

ir@jinmed.com

The Company also announced the launch of its updated corporate website at http://www.jinmed.com, where the fireside chat will be webcast.

About Jin Medical International Ltd.

Founded in 2006 and headquartered at Changzhou, Jiangsu Province of China, Jin Medical designs, develops, manufactures and markets wheelchairs and living aids products for people with disabilities, elderlies, and for rehabilitation application. Currently, Jin Medical already operates two manufacturing plants of approximately 230,000 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. Jin Medical is currently establishing a new facility with 430,000 square feet in Chuzhou, Anhui Province, China. Jin Medical works with more than 40 distributors in China and more than 20 international distributors. The majority of Jin Medical's wheelchair products, with more than 30 models, are sold to distributors in Japan and China. Jin Medical continuously delivers innovative wheelchair products that are both lightweight and ergonomic. For more information, please visit the Company's updated website at http://www.jinmed.com.

Forward-Looking Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may", "will", "should", "intend", "plan", "strive", "believe", "expect", "anticipate", "project", "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company's ability to achieve its goals and strategies, the Company's future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, import and export restrictions, fluctuations in general economic and business conditions, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission ("SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
ir@jinmed.com

The Chuzhou facility is situated in the heart of the Yangtze River Delta's manufacturing hub, offering strategic geographical and supply chain advantages. Once fully operational, the project is anticipated to generate a substantial annual output capacity that will significantly enhance Jin Medical's comprehensive manufacturing capabilities in premium mobility products.

Dr. Erqi Wang, Chairman and CEO of Jin Medical stated, "The completion of this project will support our strategic goal of optimizing global production capacities. The Chuzhou base will strengthen the resilience of our supply chain and accelerate our response to both domestic and international market demands." According to the Company's strategic plan, the facility will prioritize production of mid-to-high-end electric wheelchairs and senior mobility scooters during its initial phase, utilizing automated production lines and highly efficient protocols to improve cost control and product quality consistency.

Industry experts note that Jin Medical's expansion coincides with the growing global demand for assistive devices driven by global aging trend. Located in a region with robust manufacturing infrastructure, the Chuzhou facility is expected to enhance Jin Medical's market competitiveness through efficient scaled production. The Company reaffirms its commitment to executing the project as planned and creating sustained value for shareholders through efficient execution.

About Jin Medical International Ltd.

Founded in 2006 and headquartered at Changzhou, Jiangsu Province of China, Jin Medical designs, develops, manufactures and markets wheelchairs and living aids products for people with disabilities, elderlies, and for rehabilitation application. Currently, Jin Medical already operates two manufacturing plants of approximately 230,000 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. Jin Medical is currently establishing a new facility with 430,000 square feet in Chuzhou, Anhui Province, China. Jin Medical works with more than 40 distributors in China and more than 20 international distributors. The majority of Jin Medical's wheelchair products, with more than 30 models, are sold to distributors in Japan and China. Jin Medical continuously delivers innovative wheelchair products that are both lightweight and ergonomic. For more information, please visit: http://www.zhjmedical.com.

Forward-Looking Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may", "will", "should", "intend", "plan", "strive", "believe", "expect", "anticipate", "project", "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company's ability to achieve its goals and strategies, the Company's future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, import and export restrictions, fluctuations in general economic and business conditions, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission ("SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

ir@zhjmedical.com